NCT06566092View on ClinicalTrials.gov

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2028

Conditions
Soft Tissue SarcomaPrimary Central Nervous System CarcinomaMelanomaRhabdomyosarcomaEwing Sarcoma
Interventions
BIOLOGICAL

LN-145/LN-144

A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.

Trial Locations (5)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

14203

RECRUITING

Roswell Park Cancer Institute, Buffalo

33701

RECRUITING

Johns Hopkins All Children's Hospital, St. Petersburg

80045

RECRUITING

Children's Hospital of Colorado, Aurora

08901

RECRUITING

Rutgers Cancer Institute, New Brunswick

Sponsors
All Listed Sponsors
lead

Iovance Biotherapeutics, Inc.

INDUSTRY

NCT06566092 - Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Biotech Hunter | Biotech Hunter